The Patented Medicines (Notice of Compliance) Regulations (PMNOC Regulations) require that any section 6(1) action be brought within 45 days after the day on which the first person is served with a notice of allegation (NOA). The Federal Court has permitted such an action relating to dolutegravir (ViiV’s TIVICAY) to continue even though it was not commenced within this 45-day time limit: ViiV v Sandoz, 2020 FC 1040. Sandoz had brought a motion for summary judgment or, in the alternative, to strike the action, arguing that ViiV was statute-barred from commencing the action. The action was not commenced within 45 days of service of the NOA because of COVID-19 related issues. The Court held that the 45-day time limit for starting the action was suspended under the Time Limits and Other Periods Act (COVID-19) from March 13, 2020 to July 30, 2020. Accordingly, Sandoz’s motion was dismissed.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
FCA finds Teva would directly infringe and induce infringement of Janssen’s paliperidone palmitate patent
As previously reported, the Federal Court found that Teva would directly infringe but not induce infringement of certain claims of Canadian Patent No. 2,655,335 (335 patent) regarding its paliperidone...Read More -
Supreme Court of Canada denies Apotex leave to appeal ONCA olanzapine Statutes of Monopolies decision
Eli Lilly had successfully obtained an order of prohibition against Apotex relating to Canadian Patent No. 2,041,113, which was later found invalid in a decision involving Novopharm (affirmed on appea...Read More -
Apotex’s section 8 claim for Apo-Atomoxetine dismissed
On March 30, 2023, the Ontario Superior Court of Justice dismissed Apotex’s claim under section 8 of the Patented Medicines (Notice of Compliance) Regulations relating to Apo-Atomoxetine (Lilly’s STRA...Read More